News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ICON Awarded Best CRO At World Vaccines Congress 2014


4/2/2014 9:58:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Dublin, Ireland, 2 April, 2014 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been named Best Clinical Research Organisation in the Vaccine Industry Excellence (ViE) Awards. ICON was presented with the award at the World Vaccine Congress which took place in Washington last week.

The ViE Awards honour individuals, organisations and initiatives that have made significant contributions to innovation in the field of vaccines over the past 12 months. ICON was selected by a panel of global biotechnology industry stakeholders as the best CRO according to the following criteria:

• Range of services provided in niche and core therapeutic areas.
• Methods of performance improvement or introduction of new services.
• Attention to and quality of relationships with clients.
• Reaching of milestones and final/ongoing outcomes.
• Building and maintaining existing and long-term partnerships.

“We are proud be recognised by the world’s biotechnology companies as the industry’s best CRO,” commented Dr. Steve Cutler, Chief Operating officer, ICON plc. “Through the expertise of our Vaccine Centre of Excellence, which combines in depth vaccine experience with enabling technologies such as Firecrest and ICONIK, we help our customers exceed study milestones and take time and cost from vaccine development. This award is also recognition of the hard work and dedication of the ICON vaccines team and I’m delighted to see their efforts being applauded by the industry.”

Commenting on ICON’s award, Mark Lacy, President and CEO at Benchmark Research, a provider of investigator site services, said: “It was a great honour to present ICON with the "Best CRO" award from such a distinguished list of finalists. Vaccine studies are a key part of our business and in our experience ICON outperforms others in all aspects of vaccine trials, including quality of start-up, enrolment planning, data collection and retention management.”

About the ViE Awards
The World Vaccine Congress & Expo, now in its 14th year, is the largest and most comprehensive event in the industry. Covering everything from the latest R&D to manufacturing to corporate development strategies, the Congress hosts the only awards ceremony dedicated to the vaccine industry. The ViE Awards honour individuals, organisations and initiatives which have made significant contributions over the past 12 months to innovation in the field of vaccines.

About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 10,300 employees, operating from 78 locations in 37 countries.

Further information is available at www.iconplc.com

ICON Media Contact
Rebecca Power
Weber Shandwick
Tel: +44 (0) 207 067 0866
RPower@webershandwick.com

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
ICON
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES